The Cost Effectiveness of Screening Newborns for Congenital Adrenal Hyperplasia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess the cost effectiveness of newborn screening for congenital adrenal hyperplasia (CAH) in the U.S. newborn population. METHODS: We constructed a decision model to estimate the incremental cost-effectiveness ratio (ICER) of CAH screening compared to a strategy of no screening. Two types of cost effectiveness analyses (CEA) were conducted to measure ICER as net cost per life year (LY): (1) traditional CEA with sensitivity and scenario analyses, and (2) probabilistic CEA. RESULTS: ICERs for (1) base-case analysis in traditional CEA and (2) probabilistic CEA were USD 292,000 and USD 255,700 per LY saved in 2005 USD, respectively. ICERs were particularly sensitive to assumptions regarding the mortality rate for the salt wasting type of CAH, in a range from 2 to 9%. The ICERs for best-case and worst-case scenarios were USD 30,900 and USD 2.9 million per LY saved, respectively. CONCLUSIONS: Using common benchmarks for cost effectiveness, our results indicate that CAH screening would be unlikely to be considered cost effective unless assumptions favorable to screening were adopted, although it could meet economic criteria used to assess U.S. regulatory policies. A limitation is that the analysis excludes outcomes such as correct assignment of gender and quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent estimates have ranged widely from $20,000 (59) to $250,000 to $300,000 (60) per qualityadjusted life year.”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [60]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
Self-citationPriorities Among Effective Clinical Preventive Services
Maciosek, M. V., Coffield, A. B., Edwards, N. M., Flottemesch, T. J., Goodman, M. J., & Solberg, L. I. (2006) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2006.03.012 · Cited by 625 · cited 1×
“As an alternative to a fixed benchmark, one can compare ICERs with estimated ICERs for other preventive services that are accepted as providing good value. According to a recent analysis, one fifth of all clinical preventive services recommended by the U.S. Preventive Services Task Force cost more than USD 165,000 per…”
BackgroundWhat Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation?
Ubel, P. A., Hirth, R. A., Chernew, M. E., & Fendrick, A. M. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.14.1637 · Cited by 588
Newborn screening: toward a uniform screening panel and system—executive summary
Watson, M. S., Mann, M. Y., Lloyd-Puryear, M. A., Rinaldo, P., Howell, R. R., & American College of Medical Genetics Newborn Screening Expert Group (2006) · Pediatrics · doi:10.1542/peds.2005-2633i · Cited by 494
Accounting for future costs in medical cost-effectiveness analysis
Meltzer, D. (1997) · Journal of Health Economics · doi:10.1016/s0167-6296(96)00507-3 · Cited by 444
Therrell, B. L., Berenbaum, S. A., Manter-Kapanke, V., Simmank, J., Korman, K., Prentice, L., Gonzalez, J., & Gunn, S. (1998) · Pediatrics · doi:10.1542/peds.101.4.583 · Cited by 344
Neonatal screening in Europe; the situation in 2004
Loeber, J. G. (2007) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-007-0644-5 · Cited by 249 · cited 1×
“Elsewhere, practice is mixed, with 12 European countries having adopted it as of 2004 [”
BackgroundNeonatal screening for congenital adrenal hyperplasia
White, P. C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.148 · Cited by 240
Newborn screening for congenital adrenal hyperplasia
Therrell, B. L. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(08)70017-3 · Cited by 221
Age Differences in the Value of Statistical Life: Revealed Preference Evidence
Aldy, J. E., & Viscusi, W. K. (2007) · Review of Environmental Economics and Policy · doi:10.1093/reep/rem014 · Cited by 220
Research works printed but not linked: 1
- [2]National Newborn Screening and Genetics Resource Center: National Newborn Screening Report – 2000 Austin, TX, The National Newborn Screening and Genetics Resource Center, February 2003. [Google Scholar]
Cited by
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
“Calculations of costs per lifeyear saved are sensitive to the assumed death rate, and recent estimates have ranged widely from $20,000 (32) to $250,000–300,000 (33).”
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
Neonatal screening for congenital adrenal hyperplasia
White, P. C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.148 · Cited by 240
Population Screening for Genetic Disorders in the 21st Century: Evidence, Economics, and Ethics
Grosse, S. D., Rogowski, W. H., Ross, L. F., Cornel, M. C., Dondorp, W. J., & Khoury, M. J. (2010) · Public Health Genomics · doi:10.1159/000226594 · Cited by 138
“states that have set cost-benefit or cost-effectiveness as a criterion have made it sufficiently loose for it to not be restrictive in practice [59] . In the United Kingdom, although costeffectiveness is a stated criterion for the National Screening Committee [ 15 ] , it does not appear to have played a determining ro…”
BackgroundMethodInfluentialSelf-citationCoulm, B. (2012) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2011.774 · Cited by 78
Incidence and clinical features of congenital adrenal hyperplasia in Great Britain
Khalid, J. M., Oerton, J. M., Dezateux, C., Hindmarsh, P. C., Kelnar, C. J., & Knowles, R. L. (2012) · Archives of Disease in Childhood · doi:10.1136/archdischild-2011-300234 · Cited by 64
Decision analysis, economic evaluation, and newborn screening: challenges and opportunities
Prosser, L. A., Grosse, S. D., Kemper, A. R., Tarini, B. A., & Perrin, J. M. (2012) · Genetics in Medicine · doi:10.1038/gim.2012.24 · Cited by 50
“38 Commonly, cost-effectiveness analyses assign testing cost based on data from just one state, which does not adequately reflect variability across states, therefore limiting the ability to draw generalizable conclusions.”
InfluentialSelf-citationOptimizing Newborn Screening for Congenital Adrenal Hyperplasia
White, P. C. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.02.008 · Cited by 56
Huynh, T., McGown, I. N., Cowley, D. M., Nyunt, O., Leong, G. M., Harris, M. A., & Cotterill, A. M. (2009) · PubMed Central · Cited by 60
Congenital adrenal hyperplasia and the second newborn screen
Chan, C. L., McFann, K., Taylor, L., Wright, D., Zeitler, P. S., & Barker, J. M. (2013) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2013.01.002 · Cited by 46
Kopacek, C., de Castro, S. M., Prado, M. J., da Silva, C. M. D., Beltrão, L. A., & Spritzer, P. M. (2017) · BMC Pediatrics · doi:10.1186/s12887-016-0772-x · Cited by 36
Thirty-Year Lessons from the Newborn Screening for Congenital Adrenal Hyperplasia (CAH) in Japan
Tsuji‐Hosokawa, A., & Kashimada, K. (2021) · International Journal of Neonatal Screening · doi:10.3390/ijns7030036 · Cited by 34
Clinical impact and cost efficacy of newborn screening for congenital adrenal hyperplasia
Fox, D. A., Ronsley, R., Khowaja, A. R., Haim, A., Vallance, H., Sinclair, G., & Amed, S. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.12.057 · Cited by 28
Need and Viability of Newborn Screening Programme in India: Report from a Pilot Study
Raveendran, A., Chacko, T. J., Prabhu, P. M., Varma, R., Lewis, L., Rao, P., Shetty, P., Mallimoggala, Y. S. P., Hedge, A., Nayak, D. M., et al. (2022) · International Journal of Neonatal Screening · doi:10.3390/ijns8020026 · Cited by 29
de Miranda, M. C., Haddad, L. B. D. P., Madureira, G., Mendonca, B. B., & Bachega, T. A. S. S. (2019) · Journal of the Endocrine Society · doi:10.1210/jendso/bvz013 · Cited by 22
“Therefore, CAH-NBS has not been considered to be a cost-effective diagnostic tool [13].”
BackgroundTriagem neonatal para hiperplasia adrenal congênita
Barra, C. B., Silva, I. N., Pezzuti, I. L., & Januário, J. N. (2012) · Revista da Associação Médica Brasileira · doi:10.1590/s0104-42302012000400017 · Cited by 24
Grosse, S. D., & Vliet, G. V. (2020) · International Journal of Neonatal Screening · doi:10.3390/ijns6040082 · Cited by 22
Self-citationVotava, F., Novotná, D., Kračmar, P., Vinohradská, H., Stahlova-Hrabincova, E., Vrzalová, Z., Neumann, D., Malíková, J., Lebl, J., & Matern, D. (2012) · European Journal of Pediatrics · doi:10.1007/s00431-011-1656-6 · Cited by 19
“Therefore, false positive results are a significant problem in NBS for CAH as it creates emotional stress and financial burden on families and the health care system [15, 20].”
Backgroundde Miranda, M. C., Haddad, L. B. D. P., Trindade, E. M., Cassenote, A. J. F., Hayashi, G. Y., Damiani, D., Costa, F. C., Madureira, G., Mendonca, B. B., & Bachega, T. A. S. S. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.659492 · Cited by 16
“This probability was based on the proportion of patients with the SW form diagnosed before dehydration and those with the SV form diagnosed in the first 30 days of life in our unscreened cohort (20); the average between these proportions and the one previously published by Yoo and Grosse was used in the base case anal…”
BackgroundMethodResultInfluentialIs it time to commence newborn screening for congenital adrenal hyperplasia in Australia?
Wu, J. Y., Sudeep, Cowley, D. M., Harris, M. A., McGown, I. N., & Cotterill, A. M. (2011) · The Medical Journal of Australia · doi:10.5694/mja11.10284 · Cited by 15
Neonatal screening for congenital adrenal hyperplasia
Barra, C. B., Silva, I. N., Pezzuti, I. L., & Januário, J. N. (2012) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(12)70229-1 · Cited by 16
Vliet, G. V., & Grosse, S. D. (2021) · médecine/sciences · doi:10.1051/medsci/2021053 · Cited by 13
“Two published CEAs of NBS for CAH in the USA yielded conflicting results as to whether NBS would be considered cost-effective relative to other preventive strategies [51, 52].”
Self-citationThe case for newborn screening for congenital adrenal hyperplasia in Australia
Warne, G. L., Armstrong, K. L., Faunce, T., Wilcken, B. M., Boneh, A., Geelhoed, E. A., & Craig, M. E. (2010) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2010.tb03432.x · Cited by 12
An insight into Indonesia's progress for newborn screening program: What is currently going on
Octavius, G. S., Daleni, V. A., & Sagala, Y. D. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33479 · Cited by 15
“However, the incremental cost-effectiveness ratio (ICER) of CAH screening yields USD 30,900 and USD 2.9 million per life-year saved for best-case and worst-case scenarios, respectively, as compared to no screening [74].”
InfluentialInternational Newborn Screening Practices for the Early Detection of Congenital Adrenal Hyperplasia
Conlon, T. A., Hawkes, C. P., Brady, J. J., Loeber, J. G., & Murphy, N. (2023) · Hormone Research in Paediatrics · doi:10.1159/000530754 · Cited by 9
“The cost effectiveness of CAH NBS has also been debated [53 – 56], and further research is needed to determine the impact of improved screening protocols on the economic value of screening.”
BackgroundImpact of Newborn Screening on Clinical Presentation of Congenital Adrenal Hyperplasia
Navardauskaitė, R., Banevičiūtė, K., Songailienė, J., Grigalionienė, K., Čereškevičius, D., Šukys, M., Mockevičienė, G., Smirnova, M., Utkus, A., & Verkauskienė, R. (2021) · Medicina · doi:10.3390/medicina57101035 · Cited by 11
Rivero‐Arias, O., Png, M. E., White, A. L., Yang, M., Phillips, T., Hinton, L., Boardman, F., McNiven, A., Fisher, J., Thilaganathan, B., et al. (2024) · Health Technology Assessment · doi:10.3310/pytk6591 · Cited by 11
Fernández, J. R. A. (2016) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2016.08.006 · Cited by 8
Neonatal screening for congenital adrenal hyperplasia
Barra, C. B., Silva, I. N., Pezzuti, I. L., & Januário, J. N. (2012) · Revista da Associação Médica Brasileira · doi:10.1016/s0104-4230(12)70229-4 · Cited by 7
Lamsal, R., Smith, H. S., & Grosse, S. D. (2025) · Applied Health Economics and Health Policy · doi:10.1007/s40258-025-01013-3 · Cited by 5
“Two CEAs [13, 60] of NBS for CAH in the US did not find NBS cost-effective compared to the no screening strategy using a commonly used threshold or benchmark value for quality-adjusted life years (QALYs) of 50,000 US dollars (US $) per life year (LY) saved or US $50,000 per QALY gained [61].”
Self-citationSilveira, E. L. (2008) · Lume (Universidade Federal do Rio Grande do Sul) · Cited by 2
de Miranda, M. C. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2020.tde-29102020-162042
(2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e328339f31e
Newborn Screening in India: A Systematic Review and Meta-AnalysisPreprint
Chauhan, M., Mahendru, A., Bhardwaj, A., Suravajhala, P., Kapoor, S., & Polipalli, S. K. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5051990 · Cited by 1
Jafar, B., Kilberg, M. J., & Vogiatzi, M. G. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114597
Metadata
- Authors
- Yoo, B. K., & Grosse, S. D.
- Affiliations
- University of Rochester Medicine (US)
- University of Rochester (US)
- ORCID
- Grosse, S.D.
- Venue
- Public Health Genomics
- Publisher
- S. Karger AG
- Published
- 2008-09-14
- Volume
- 12
- Issue
- 2
- Pages
- 67-72
- ISSN
- 1422-2795 (ISSN-L)
- 1662-4246
- 1662-8063
- PMC
- PMC6706242
- OpenAlex
- W1971371806
- Cited by
- 37
- References
- 26
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 3 · 2019: 2 · 2018: 1 · 2017: 1 · 2016: 1 · 2013: 2 · 2012: 7
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Update notices
- erratum (2008-09-14)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- karger.com/pages/terms-and-conditions (vor)
- karger.com/pages/terms-and-conditions (tdm)
- Locations
- Public Health Genomics (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- congenital adrenal hyperplasia, newborn screening, cost-effectiveness, incremental cost-effectiveness ratio, mortality assumptions, decision models, screening policy
- MeSH terms
- Adrenal Hyperplasia, Congenital, Cost-Benefit Analysis, Humans, Infant, Newborn, Predictive Value of Tests, Probability, Public Health, Sensitivity and Specificity, United States, Incidence, Neonatal Screening, Outcome Assessment, Health Care, Quality-Adjusted Life Years
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.